



Contacts: Bret L. Udem
Media Relations
Tel. (425) 493-2293
Fax. (425) 493-2010

FOR RELEASE
March 3, 2004

**COMBIMATRIX TO WEBCAST PRESENTATION
AT THE SG COWEN 24th ANNUAL HEALTH CARE CONFERENCE**

Newport Beach, Calif. – (BUSINESS WIRE) – March 3, 2004 – Acacia Research Corporation (Nasdaq: CBMX:ACTG) announced today that its CombiMatrix group will present at the SG Cowen 24th Annual Health Care Conference at the Boston Marriott Copley Place Hotel, located in Boston, Massachusetts. Dr. Amit Kumar, President and CEO of CombiMatrix will present an overview of the company.

A live transmission of the presentation will take place at 11:15 am ET on Wednesday, March 11, 2004. An archived webcast will be available for 30 days. To access the live webcast or archived presentation, please go to www.combimatrix.com/news_events.htm.

ABOUT ACACIA RESEARCH COPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix's technology has a wide range of applications including DNA synthesis/diagnostics, siRNA synthesis, drug discovery, and immunochemical detection. CombiMatrix provides DNA arrays to researchers under the CustomArrayTM brand.

CombiMatrix's Express Tracksm drug discovery program is a systems biology approach, using its technology, to target common viral diseases with siRNA compounds. The initial focus of Express Tracksm includes the following viral diseases:

<u>Virus</u>	<u>Collaborator</u>
SARS	NIAID/USAMRIID
HIV type 1	irsiCaixa-Dr. Bonaventura Clotet
HIV type 2	To Be Announced
West Nile virus	To Be Announced
Human Papillomavirus type 16	To Be Announced
Human Herpes 8 (Kaposi's sarcoma)	To Be Announced

Smallpox (Variola)	To Be Announced
Influenza virus A	To Be Announced
Influenza virus B	To Be Announced
Hepatitis C	To Be Announced

CombiMatrix is also establishing applications of its arrays through other partnerships as follows:

<u>Project</u>	<u>Collaborator</u>
Cancer Diagnosis (Lymphoma) RNA Drug Targets	University of Washington/Rational Diagnostics Professor Gregory L. Verdine, Harvard University
<u>Parasite</u> Leishmania Trypasonoma	Seattle Biomedical Research Institute Seattle Biomedical Research Institute

The Acacia Technologies Group develops, acquires, and licenses patented technologies. Acacia's DMT technology, which is supported by 5 U.S. and 31 foreign patents, relates to audio and audio/video transmission and receiving systems commonly known as audio-on-demand, video-on-demand, and audio/video streaming, and is used for distributing digital content via several means including Internet, cable, satellite and wireless systems.

Acacia Research-Acacia Technologies (Nasdaq: ACTG) and Acacia Research-CombiMatrix (Nasdaq: CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.